Logos Global Management as of June 30, 2024
Portfolio Holdings for Logos Global Management
Logos Global Management holds 53 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 14.9 | $185M | 2.0M | 92.71 | |
| Sarepta Therapeutics (SRPT) | 8.3 | $103M | 650k | 158.00 | |
| Apellis Pharmaceuticals Call Option (APLS) | 7.4 | $92M | 2.4M | 38.36 | |
| Structure Therapeutics Sponsored Ads Call Option (GPCR) | 4.9 | $61M | 1.6M | 39.27 | |
| Ideaya Biosciences (IDYA) | 4.8 | $60M | 1.7M | 35.11 | |
| Argenx Se Sponsored Adr (ARGX) | 4.7 | $58M | 135k | 430.04 | |
| Merus N V (MRUS) | 4.0 | $50M | 850k | 59.17 | |
| Revolution Medicines (RVMD) | 3.7 | $47M | 1.2M | 38.81 | |
| Disc Medicine (IRON) | 3.4 | $42M | 925k | 45.07 | |
| Ocular Therapeutix (OCUL) | 2.8 | $35M | 5.2M | 6.84 | |
| Olema Pharmaceuticals (OLMA) | 2.8 | $35M | 3.2M | 10.82 | |
| Vera Therapeutics Cl A (VERA) | 2.8 | $34M | 950k | 36.18 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.7 | $33M | 750k | 43.97 | |
| Janux Therapeutics (JANX) | 2.5 | $31M | 750k | 41.89 | |
| Xencor (XNCR) | 2.3 | $28M | 1.5M | 18.93 | |
| Silence Therapeutics Ads (SLN) | 2.3 | $28M | 1.5M | 19.00 | |
| Annexon (ANNX) | 1.9 | $24M | 4.8M | 4.90 | |
| Akero Therapeutics (AKRO) | 1.5 | $19M | 800k | 23.46 | |
| Design Therapeutics (DSGN) | 1.4 | $17M | 5.0M | 3.35 | |
| Immunovant (IMVT) | 1.2 | $15M | 575k | 26.40 | |
| Nuvalent Inc-a (NUVL) | 1.2 | $15M | 195k | 75.86 | |
| Xenon Pharmaceuticals (XENE) | 1.2 | $15M | 375k | 38.99 | |
| Ionis Pharmaceuticals (IONS) | 1.2 | $14M | 300k | 47.66 | |
| Stoke Therapeutics (STOK) | 1.1 | $14M | 1.1M | 13.51 | |
| Erasca (ERAS) | 1.1 | $14M | 5.9M | 2.36 | |
| Enliven Therapeutics (ELVN) | 1.1 | $14M | 595k | 23.37 | |
| Spyre Therapeutics Com New (SYRE) | 1.1 | $14M | 575k | 23.51 | |
| Engene Holdings (ENGN) | 0.9 | $11M | 1.2M | 9.43 | |
| Cybin Ord | 0.9 | $11M | 40M | 0.27 | |
| Skye Bioscience Com New (SKYE) | 0.8 | $10M | 1.3M | 8.01 | |
| Elevation Oncology (ELEV) | 0.8 | $10M | 3.9M | 2.70 | |
| Dyne Therapeutics (DYN) | 0.8 | $9.4M | 265k | 35.29 | |
| Fulcrum Therapeutics Call Option (FULC) | 0.7 | $9.3M | 1.5M | 6.20 | |
| Biohaven (BHVN) | 0.7 | $8.7M | 250k | 34.71 | |
| Relay Therapeutics (RLAY) | 0.7 | $8.5M | 1.3M | 6.52 | |
| Trevi Therapeutics (TRVI) | 0.7 | $8.3M | 2.8M | 2.98 | |
| Rocket Pharmaceuticals (RCKT) | 0.6 | $7.5M | 350k | 21.53 | |
| Compass Pathways Sponsored Ads (CMPS) | 0.6 | $7.0M | 1.2M | 6.04 | |
| Avalo Therapeutics Com New (AVTX) | 0.5 | $6.7M | 539k | 12.47 | |
| Lineage Cell Therapeutics In (LCTX) | 0.4 | $4.7M | 4.7M | 1.00 | |
| Atyr Pharma Com New (ATYR) | 0.4 | $4.7M | 3.0M | 1.56 | |
| Astria Therapeutics (ATXS) | 0.4 | $4.6M | 500k | 9.10 | |
| Rapport Therapeutics (RAPP) | 0.4 | $4.4M | 209k | 20.93 | |
| Nextcure (NXTC) | 0.3 | $4.0M | 2.5M | 1.59 | |
| Neumora Therapeutics (NMRA) | 0.2 | $2.9M | 300k | 9.83 | |
| Allakos | 0.2 | $2.9M | 2.9M | 1.00 | |
| Adverum Biotechnologies Com New (ADVM) | 0.2 | $2.9M | 417k | 6.86 | |
| Applied Therapeutics (APLT) | 0.2 | $2.7M | 600k | 4.44 | |
| Cartesian Therapeutics Com New (RNAC) | 0.2 | $2.4M | 90k | 27.01 | |
| Unicycive Therapeutics | 0.1 | $1.7M | 3.5M | 0.50 | |
| Io Biotech (IOBT) | 0.0 | $578k | 494k | 1.17 | |
| Boundless Bio (BOLD) | 0.0 | $433k | 118k | 3.68 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $11k | 67k | 0.16 |
